Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109.
Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109.
J Biol Chem. 2020 May 1;295(18):5906-5917. doi: 10.1074/jbc.RA119.011869. Epub 2020 Mar 12.
We previously reported that overexpression of cytochrome P450 family 24 subfamily A member 1 (CYP24A1) increases lung cancer cell proliferation by activating RAS signaling and that CYP24A1 knockdown inhibits tumor growth. However, the mechanism of CYP24A1-mediated cancer cell proliferation remains unclear. Here, we conducted cell synchronization and biochemical experiments in lung adenocarcinoma cells, revealing a link between CYP24A1 and anaphase-promoting complex (APC), a key cell cycle regulator. We demonstrate that CYP24A1 expression is cell cycle-dependent; it was higher in the G-M phase and diminished upon G entry. CYP24A1 has a functional destruction box (D-box) motif that allows binding with two APC adaptors, CDC20-homologue 1 (CDH1) and cell division cycle 20 (CDC20). Unlike other APC substrates, however, CYP24A1 acted as a pseudo-substrate, inhibiting CDH1 activity and promoting mitotic progression. Conversely, overexpression of a CYP24A1 D-box mutant compromised CDH1 binding, allowing CDH1 hyperactivation, thereby hastening degradation of its substrates cyclin B1 and CDC20, and accumulation of the CDC20 substrate p21, prolonging mitotic exit. These activities also occurred with a CYP24A1 isoform 2 lacking the catalytic cysteine (Cys-462), suggesting that CYP24A1's oncogenic potential is independent of its catalytic activity. CYP24A1 degradation reduced clonogenic survival of mutant -driven lung cancer cells, and calcitriol treatment increased CYP24A1 levels and tumor burden in mice. These results disclose a catalytic activity-independent growth-promoting role of CYP24A1 in mutant -driven lung cancer. This suggests that CYP24A1 could be therapeutically targeted in lung cancers in which its expression is high.
我们之前报道过,细胞色素 P450 家族 24 亚家族 A 成员 1(CYP24A1)的过表达通过激活 RAS 信号而增加肺癌细胞增殖,并且 CYP24A1 的敲低抑制肿瘤生长。然而,CYP24A1 介导的癌细胞增殖的机制尚不清楚。在这里,我们在肺腺癌细胞中进行了细胞同步化和生化实验,揭示了 CYP24A1 与细胞周期调控的关键因子后期促进复合物(APC)之间的联系。我们证明 CYP24A1 的表达与细胞周期有关;它在 G-M 期更高,并在 G1 期进入时减少。CYP24A1 具有功能性破坏框(D-box)基序,允许与两个 APC 衔接子,CDC20 同源物 1(CDH1)和细胞分裂周期 20(CDC20)结合。然而,与其他 APC 底物不同,CYP24A1 作为伪底物起作用,抑制 CDH1 活性并促进有丝分裂进展。相反,CYP24A1 D-box 突变体的过表达会损害 CDH1 结合,允许 CDH1 过度激活,从而加速其底物细胞周期蛋白 B1 和 CDC20 的降解,并积累 CDC20 底物 p21,延长有丝分裂退出。这些活性也发生在缺乏催化半胱氨酸(Cys-462)的 CYP24A1 同工型 2 中,表明 CYP24A1 的致癌潜力与其催化活性无关。CYP24A1 的降解降低了突变驱动的肺癌细胞的集落形成存活能力,而骨化三醇处理增加了 小鼠中 CYP24A1 水平和肿瘤负担。这些结果揭示了 CYP24A1 在突变驱动的肺癌中具有独立于其催化活性的促生长作用。这表明 CYP24A1 可以作为表达水平高的肺癌的治疗靶点。